INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Pulmonary & Nasal Drug Delivery
170
Issue No #170 April 2025
April 17th, 2025
Download PDF
Issue 170 - Apr 2025
Inside the magazine
PULMONARY
Jonathan Mulpas
Aptar Pharma
THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS
Jonathan Mulpas discusses how advanced inhaled drug delivery devices, such as dry powder inhalers and non-propellant liquid inhalers, can meet currently unmet needs in the inhalation space, focusing on devices that Aptar and its partners are developing to realise this potential and the expertise that Aptar can offer in this area.
EXPERT VIEW
Dr Heather Jameson
BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS
Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.
EXPERT VIEW
Kamaal de Silva
SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?
Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.
PULMONARY
Dr Clair Brooks
Copley Scientific
DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES
Clair Brooks looks at some of the in-use issues and patient effects that good design of devices for orally inhaled drug products can address within the context of regulatory requirements for the demonstration of robustness.
PULMONARY
Dr Alan Watts
Catalent Pharma Solutions
MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION
Alan Watts, Yusuf Ahmed and Gabriela Dujovny discuss manufacturing methods for inhalation powders and explain how moisture protection is an essential consideration throughout the manufacturing process.
RESPIRATORY
Dr Philippe Rogueda
Merxin Ltd
TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?
Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.
NASAL
Sophie Conte
Nemera
NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING
Sophie Conte and Alain Regard, describe Nemera’s journey in nose-to-brain device development, highlighting the evaluation tools, methods and usability testing developed in-house to steer innovative device design and engineering.
EXPERT VIEW
Eric Kaneps
MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING
Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.
PULMONARY
Dr Carolina Dantas
Pulmotree Medical
REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH
Carolina Dantas, Ulf Krueger and Howard Burnett discuss the critical need for precision when delivering biologics to the lungs, how PULMOTREE’s Kolibri is able to achieve this using guided breathing, and how the use of realistic breathing profiles can improve outcomes and decrease risk with in vitro and in silico testing.
CONFERENCE SHOWCASE
CONFERENCE PREVIEW: SMI.LONDON
Join colleagues from across the inhalation space at SMI.London 2025, the only conference dedicated to soft mist inhalers (SMIs) worldwide. The event will take place on Wednesday, June 25, 2025, at the Pullman London St Pancras, hosted by Merxin.
Top
